NEW YORK, Jan. 19, 2005 (PRIMEZONE) -- Amazon Biotech, Inc. (OTCBB:AMZB) today announced the appointment of Anthony J. Mangia, M.D., F.A.C.P, to its Scientific Advisory Board.
Dr. Mangia has over 20 years experience as an expert consultant on infectious diseases. Dr. Mangia currently consults to a variety of hospitals and healthcare centers in the New Jersey area including: St. Francis Hospital (Jersey City, NJ), Christ Hospital (Jersey City, NJ), Department of Veterans Affairs (Orange, NJ), Meadowlands Hospital Medical Center (Seacaucus, NJ), Jersey Medical Center (Jersey City, NJ) and Greenville Hospital (Jersey City, NJ). Additionally, since 1991 Dr. Mangia has run a full-time infectious disease practice. His appointment will assist the Phase I/II Study due to commence on Amazon Biotech's Immune Modulator Drug AMZ0026, which has IND approval from the FDA.
Academically, Dr. Mangia has been a full time professor on Infectious Disease at Jersey City Medical Center (Jersey City, NJ), Seton Hall (South Orange, NJ), and the Veterans Affairs Medical Center (East Orange, NJ). He completed his medical training at the University of Geneva, postgraduate training at New York Methodist Hospital, and Fellowship training at New Jersey Medical School.
Dr Chinnici CEO of Amazon biotech said, "I am extremely pleased to welcome Dr. Mangia to our Company's Board. His dedication to health and medicine will be beneficial for shaping the future of Amazon Biotech as a global leader in the fight against HIV/AIDS. Dr. Mangia's strong life science background and relationship with leading hospitals will significantly enhance the knowledge base of our Board," commented Dr. Chinnici, CEO of Amazon Biotech. "With his many years of specialized experience in infectious disease, Dr. Mangia has a deep and thorough understanding of the fundamentals of our treatment approach."
Dr Mangia said, "I am pleased to accept the position on the Scientific Advisory Board. As known, recent studies have shown Promising results using Nutritional therapy for Aids. Nutritional based therapy may be an important Immune Modulator and delay the progression of HIV infection to Aids. I look forward to working with Amazon Biotech Inc. on this exciting venture."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a Natural Plant Pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company intends to initiate Phase I/II clinical studies of AMZ 0026 shortly, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.